ArticleInvestigational new drugs2025

Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity.

Arun A Azad et al.PubMed ↗Publisher ↗

No numbers read from the abstract.